Form 4: Lexeo Therapeutics Executive Sells Shares

Lexeo Therapeutics Chief Operating Officer Jose Manuel Otero sold 1,302 shares of common stock for $5.074 per share, totaling $6,607, to cover tax obligations on restricted stock units.

Summary

• Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics, Inc., reported a transaction on May 18, 2026.
• Otero sold 1,302 shares of common stock at a weighted average price of $5.074 per share.
• The total value of the transaction was approximately $6,607.
• This sale was conducted to cover tax obligations related to the release of restricted stock units (RSUs).
• Following the transaction, Otero beneficially owns 130,088 shares of common stock, including 100,621 RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally as it represents a standard transaction for tax coverage on restricted stock units, rather than a sale indicating a lack of confidence in the company's future.

Negatives

• An executive sold company stock, which can sometimes be perceived negatively by the market, although this sale was for tax cover purposes.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. While this specific filing details a routine sale for tax purposes, any significant insider selling can be a point of attention for investors monitoring executive confidence in the company's prospects.

Stakeholder Impact

• Shareholders: The sale is for tax cover and does not necessarily reflect a negative view of the company's prospects, thus likely having a minimal direct impact on share price based on this transaction alone.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Sale, Lexeo Therapeutics, Jose Manuel Otero, Restricted Stock Units, Tax Obligations, Common Stock